Showing 5401-5410 of 5771 results for "".
- Nicox Postpones Nasdaq Listing Due to Market Volatilityhttps://modernod.com/news/nicox-postpones-nasdaq-listing-due-to-market-volatility/2479717/Nicox SA announced that due to the extreme volatility of the financial markets, it has decided to postpone its dual listing on Nasdaq, concluding that it would not be in the interest of their existing shareholders at this time, according to a company news release. The purpose of a Nasdaq l
- $4 Million Gift to Aid Construction of a Public Museum Dedicated to Vision and Eye Healthhttps://modernod.com/news/aao-announces-4-million-gift-to-aid-construction-of-a-public-museum-dedicated-to-vision-and-eye-health/2479720/The American Academy of Ophthalmology announced a project to construct the world’s first public museum dedicated to vision and eye health. The new museum will be located in San Francisco. Prominent ophthalmologist Stanley M. Truhlsen, MD, launched the project with a $4 million donation. The annou
- Spark Therapeutics Presents Three Post-hoc Analyses from Phase 3 Clinical Trial of Luxturnahttps://modernod.com/news/spark-therapeutics-presents-three-post-hoc-analyses-from-phase-3-clinical-trial-of-luxturna/2479721/Spark Therapeutics announced findings from three post-hoc analyses of data from the phase 3 clinical trial of Luxturna (voretigene neparvovec-rzyl) at the American Academy of Ophthalmology annual meeting in Chicago. Luxturna is a 1-time gene therapy for the treatment of patients with vision loss
- ProQR In-licenses Worldwide Rights to Ophthalmology Drug Candidate from Ionis Pharmaceuticalshttps://modernod.com/news/proqr-in-licenses-worldwide-rights-to-ophthalmology-drug-candidate-from-ionis-pharmaceuticals/2479723/ProQR Therapeutics announced the signing of an agreement with Ionis Pharmaceuticals to license QR-1123 (formerly IONIS-RHO-2.5Rx), an RNA medicine for autosomal dominant retinitis pigmentosa (adRP) caused by the P23H mutation in the rhodopsin (RHO) gene. “Building on th
- EyePoint Pharmaceuticals Presents Positive Yutiq 24-month Follow-up Data at AAOhttps://modernod.com/news/eyepoint-pharmaceuticals-presents-positive-yutuq-24-month-follow-up-data-at-aao/2479724/EyePoint Pharmaceuticals announced the presentation of 24-month efficacy and safety data supporting the company’s Yutiq (fluocinolone acetonide intravitreal implant) 0.18 mg 3-year micro-insert for the treatment of chronic noninfectious uveitis affecting the posterior segment of the eye. Th
- Spectralis High Magnification Module Receives FDA Clearancehttps://modernod.com/news/spectralis-high-magnification-module-receives-fda-clearance/2479726/Heidelberg Engineering announced it has received FDA clearance for its Spectralis High Magnification Module. This new module consists of a highly innovative lens and software upgrade that will be available for new and
- Novartis: Two-Year Head-to-Head Data for Brolucizumab Reaffirm Superiority vs Aflibercept in Reducing Retinal Fluid in Patients With Wet AMDhttps://modernod.com/news/novartis-two-year-head-to-head-data-for-brolucizumab-reaffirm-superiority-vs-aflibercept-in-reducing-retinal-fluid-in-patients-with-wet-amd/2479727/Novartis announced additional brolucizumab phase 3 results from year 2 (96 weeks) that reaffirmed its positive year 1 (48 weeks) findings. Brolucizumab met its primary endpoint of noninferiority versus aflibercept in best corrected visual acuity (BCVA) and exhibited superiority in key retinal out
- New STAIRWAY Study Data Shows Potential for Extended Durability with Faricimab in Wet AMDhttps://modernod.com/news/new-stairway-study-data-shows-potential-for-extended-durability-with-faricimab-in-wet-amd/2479728/Genentech announced positive results from the phase 2 STAIRWAY study which explored the extended durability of faricimab (RG7716) in the treatment of wet age-related macular degeneration (AMD). At 52 weeks, faricimab patients dosed either every 16 weeks or every 12 weeks demonstrated sustained vi
- Zeiss Introduces New Advances in Astigmatism Management and Glaucoma Imaging at AAOhttps://modernod.com/news/zeiss-introduces-new-advances-in-astigmatism-management-and-glaucoma-imaging-at-aao/2479729/The Annual Meeting of the American Academy of Ophthalmology (AAO) marks Zeiss’ U.S. launch of Total Keratometry (TK) for IOLMaster 700, offering cataract surgeons the opportu
- GenSight Biologics Enrolls First Subject in PIONEER Phase 1/2 Trial of Retinitis Pigmentosa Drug Candidatehttps://modernod.com/news/gensight-biologics-enrolls-first-subject-in-pioneer-phase-1-2-trial-of-retinitis-pigmentosa-drug-candidate/2479731/GenSight Biologics announced that the first subject was treated in the first-in-man PIONEER phase I/II clinical trial of GS030 at the Moorfields Eye Hospital in London, United Kingdom. “We are thrilled to see our second lead program, GS030, now entering the clinic. This is a fantastic achi